Quinlan Paul T 4
4 · Oruka Therapeutics, Inc. · Filed Mar 17, 2026
Research Summary
AI-generated summary of this filing
Oruka Therapeutics (ORKA) General Counsel Paul T. Quinlan Sells 733 Shares
What Happened
Paul T. Quinlan, General Counsel of Oruka Therapeutics (ORKA), sold 733 shares in a reported transaction on March 16, 2026. The shares were sold at $41.30 per share for total proceeds of $30,273. The filing indicates this was a sell-to-cover transaction to satisfy tax withholding arising from vested restricted stock units (RSUs), not a discretionary open-market trade for investment purposes.
Key Details
- Transaction date: 2026-03-16; Filing date: 2026-03-17 (timely filing).
- Transaction type: Sale (S) — 733 shares at $41.30 per share; total $30,273.
- Footnote: The sale was effected under the company’s automatic, non-discretionary sell-to-cover procedure to satisfy tax withholding on RSU vesting (F1).
- Shares owned after the transaction: not specified in the provided filing excerpt.
- No 10b5-1 plan or late-filing indication noted in this report.
Context: Sell-to-cover transactions are routine administrative sales to cover taxes when RSUs vest and do not necessarily signal the insider’s view on the company’s stock. This report documents that routine withholding sale rather than an independent decision to liquidate holdings.
Insider Transaction Report
- Sale
Common Stock
[F1]2026-03-16$41.30/sh−733$30,273→ 31,767 total
Footnotes (1)
- [F1]The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.